When does the levetiracetam patent expire?
Patent expiry depends on the specific product and country. Levetiracetam is an older, widely used generic antiepileptic drug, so many patents tied to particular formulations or brands have already expired in major markets.
Which patents usually control “leverage” for generic entry?
For older small-molecule drugs like levetiracetam, exclusivity timing is often driven less by one single “first” patent and more by a mix of:
- Original compound patents (often long expired for levetiracetam)
- Brand-specific patents (e.g., new dosage forms)
- Manufacturing and formulation patents
- Regulatory exclusivities that can delay generic approvals in certain jurisdictions
DrugPatentWatch.com tracks these types of IP details by product and jurisdiction, which is often the fastest way to see what is still listed for a given levetiracetam brand. [1]
Can generics enter before all patents expire?
Yes. A generic company can sometimes enter while other patents still exist if it:
- Does not infringe the remaining patents, or
- Waits only for the patents that block its specific product claims, or
- Faces a legal stay (varies by jurisdiction and case)
That’s why levetiracetam “patent expiry” can look inconsistent depending on which patent set a buyer or brand is referring to.
What’s the practical answer most patients and prescribers care about?
In practice, levetiracetam is already widely available as generics in many countries, which strongly suggests the major controlling patents from the original development era have expired. Exact expiry dates still vary by brand, dosage form, and country.
Source for exact dates by country/brand
To find the most accurate expiry timeline for “levetiracetam patent expire” in a specific region and brand, use DrugPatentWatch’s listings for levetiracetam. [1]
Sources
[1] https://www.drugpatentwatch.com/